Alerting Obstetric Clinicians to Boost Aspirin Use for Preeclampsia Prevention
Tests whether alerting clinicians raises aspirin use in pregnant women at high preeclampsia risk.
Plain-language title generated from the registry record
Registry title: Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia Prevention
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Mass General BrighamBoston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT07614893
- Record updated
- 29 May 2026
- Original description
Preeclampsia is a leading cause of maternal morbidity and mortality. Low-dose aspirin prophylaxis reduces preeclampsia risk among high-risk pregnant individuals but remains underused in routine clinical practice. This pragmatic cluster-randomized implementation trial will test whether clinician notification of elevated preeclampsia risk increases aspirin prophylaxis utilization among eligible pregnant individuals receiving outpatient obstetric care.Read full original descriptionShow less
A Pragmatic Cluster-Randomized Trial of Clinician Notification to Increase Aspirin Prophylaxis Utilization Among Pregnant Individuals at Elevated Risk for Preeclampsia
Preeclampsia is a leading cause of maternal morbidity and mortality. Low-dose aspirin prophylaxis reduces preeclampsia risk among high-risk pregnant individuals but remains underused in routine clinical practice. This pragmatic cluster-randomized implementation trial will test whether clinician notification of elevated preeclampsia risk increases aspirin prophylaxis utilization among eligible pregnant individuals receiving outpatient obstetric care.
Clusters will be randomized to clinician notification versus usual care. In the intervention arm, obstetric clinicians will receive notification that a patient is at elevated risk for preeclampsia and a recommendation to consider initiation of aspirin prophylaxis between 12 and 28 weeks' gestation, as clinically appropriate. The intervention does not assign participants to aspirin and does not require any study-mandated medication. All decisions regarding aspirin prophylaxis will remain at the discretion of the treating obstetric clinician and patient.
Inclusion: Pregnant individuals receiving outpatient obstetric care at participating medical centers; Age 18 years or older; Currently pregnant and within 12 to 28 weeks' gestation; Identified as having elevated predicted risk for preeclampsia as defined by USPSTSF and ACOG criteria; Receiving care from a clinician, care team, or clinic participating in the randomized implementation trial.
Exclusion: Not receiving ongoing obstetric care at a participating site; Pregnancy beyond the prespecified gestational age window for aspirin prophylaxis implementation at the time of eligibility assessment; Known contraindication to aspirin prophylaxis documented in the electronic health record.